| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_127b0a2d4a7b43528729b23a47172377 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-36 |
| filingDate |
2008-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90dc3b5ebf45d759fa83578defdc61e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_762b31ebc97893457cd7bc1c6e56023b |
| publicationDate |
2017-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2845292-C |
| titleOfInvention |
Use of arsenic compounds for treatment of pain and inflammation |
| abstract |
Use of sodium meta arsenite in the manufacture of a pharmaceutical composition formulated for oral administration for the treatment of non-cancer-associated inflammation in a mammal. Use of sodium meta arsenite in a pharmaceutical composition formulated for oral administration, for the treatment of non- cancer-associated inflammation in a mammal. A kit comprising at least one therapeutically effective dosage amount of sodium meta arsenite in a composition formulated for oral administration, wherein the therapeutically effective amount of the sodium meta arsenite is sufficient to reduce or prevent inflammation in a patient. |
| priorityDate |
2007-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |